Last updated: November 4, 2026
FLUAD is Seqirus Inc.’s adjuvanted influenza vaccine for adults aged 65 and older. The product uses the MF59 adjuvant to improve immune response in older adults. FLUAD Quadrivalent expanded coverage from three to four influenza strains, but U.S. influenza vaccines are transitioning back to trivalent formulations after the removal of the B/Yamagata lineage.
FLUAD’s commercial outlook is supported by the aging population, annual influenza vaccination demand, Medicare reimbursement, and preferential use of enhanced vaccines in older adults. Its main risks are seasonal demand volatility, government purchasing cycles, manufacturing capacity, strain changes, and competition from Fluzone High-Dose and Flublok. Public filings do not disclose standalone FLUAD or FLUAD Quadrivalent sales, so financial exposure must be assessed through Seqirus’ broader influenza-vaccine segment.
What are FLUAD and FLUAD Quadrivalent?
FLUAD is an inactivated influenza vaccine containing the MF59 adjuvant, an oil-in-water emulsion based on squalene. It is designed for adults aged 65 and older, a population with weaker immune responses to standard-dose influenza vaccines.
FLUAD Quadrivalent contains four influenza strains. The original FLUAD formulation was trivalent.
| Product |
Sponsor |
U.S. FDA status |
Target population |
Formulation |
| FLUAD |
Seqirus Inc. |
Licensed 2015 |
Adults 65+ |
Trivalent, MF59-adjuvanted |
| FLUAD Quadrivalent |
Seqirus Inc. |
Licensed 2020 |
Adults 65+ |
Quadrivalent, MF59-adjuvanted |
| FLUAD 2024-25 and later |
Seqirus Inc. |
Seasonal updates |
Adults 65+ |
Trivalent, MF59-adjuvanted |
The FDA approved FLUAD in 2015 under biologics license application BLA 125363. FLUAD Quadrivalent received FDA approval in 2020 as a supplemental update to the product’s seasonal composition and valency [1, 2].
When does FLUAD lose regulatory exclusivity?
FLUAD’s core U.S. biologic exclusivity period is tied to its first licensure in 2015. Under the Public Health Service Act, a reference biological product generally receives 12 years of reference-product exclusivity, with a four-year period during which a biosimilar application cannot be submitted [3].
| Regulatory protection |
Relevant date |
Commercial implication |
| FLUAD first U.S. licensure |
2015 |
Starts the reference-product exclusivity framework |
| Four-year biosimilar filing bar |
Expired in 2019 |
A biosimilar application could theoretically be submitted after this date |
| Twelve-year reference-product exclusivity |
Approximately 2027 |
Ends the principal statutory biologic exclusivity period |
| FLUAD Quadrivalent approval |
2020 |
Does not necessarily create a new 12-year period because it is a formulation and seasonal supplement to the same licensed product |
The practical competitive impact is more limited than the statutory dates suggest. Influenza vaccines are updated annually, and a competitor would need to address strain composition, clinical comparability, manufacturing consistency, adjuvant performance, and regulatory timing. The market has not developed a significant U.S. biosimilar pathway for seasonal influenza vaccines.
What is the Orange Book status of FLUAD?
FLUAD is not expected to have a conventional Orange Book patent listing because the Orange Book primarily covers approved drug products and their associated patents, while FLUAD is licensed as a biologic under a BLA.
The relevant regulatory records are the FDA biologics license and product labeling rather than an Orange Book entry. FLUAD’s competitive protections therefore depend on:
- Biologic exclusivity under the Public Health Service Act.
- Manufacturing know-how.
- MF59 adjuvant production and quality controls.
- Seasonal strain-selection and regulatory execution.
- Manufacturing capacity and supply contracts.
- Potential formulation, process, and use patents.
No publicly established Orange Book Paragraph IV pathway governs FLUAD in the same manner as a small-molecule drug.
What patents protect FLUAD and its MF59 adjuvant?
FLUAD’s commercial protection is based more heavily on regulatory, manufacturing, and operational barriers than on a single currently enforceable U.S. composition patent.
MF59-related intellectual property originated through the Chiron and Novartis influenza-vaccine businesses, which became part of Seqirus after CSL acquired Novartis’ influenza-vaccine business in 2015. Early MF59 patent families generally concern oil-in-water emulsions, squalene-containing adjuvants, antigen-adjuvant combinations, and methods for enhancing immune responses.
The earliest foundational MF59 patent rights are old enough that many core U.S. patent terms have likely expired or become commercially less significant. Later patent families may cover specific manufacturing parameters, antigen-adjuvant combinations, dosage forms, or methods of use, but a complete current patent landscape requires claim-level review of global family members and legal-status records.
| IP category |
Relevance to FLUAD |
Expected strength |
| Core MF59 composition patents |
Protect the general adjuvant platform |
Reduced by age and expiration of foundational families |
| Specific antigen-adjuvant combinations |
May cover selected vaccine formulations |
Potentially stronger if claims remain in force |
| Manufacturing-process patents |
Cover emulsion preparation, particle size, stability, or sterile processing |
Important practical barrier |
| Method-of-use patents |
May address immunization of older adults or immune-response enhancement |
Limited value if broad claims are expired or vulnerable |
| Seasonal strain composition |
Changes annually and is not generally protected by one durable patent |
Regulatory and operational issue |
| Trade secrets and know-how |
Cover scale-up, quality control, formulation stability, and fill-finish |
High practical importance |
Are there formulation patents for FLUAD?
Potential formulation protection is more relevant than a patent directed only to the FLUAD brand. Relevant claims may concern:
- Squalene concentration and oil-to-water ratios.
- Surfactant combinations.
- Emulsion particle-size distribution.
- Compatibility between MF59 and influenza antigens.
- Stability during storage.
- Sterile manufacturing and filling.
- Single-dose prefilled syringes.
The commercial value of these rights depends on claim scope and expiration. A competitor could potentially avoid a narrow claim through a different adjuvant, emulsion composition, process, or delivery format.
Are there method-of-use patents for FLUAD?
Method-of-use claims may address vaccination of adults aged 65 and older or the use of an adjuvanted influenza vaccine to improve immune response. Such claims face substantial validity and infringement challenges if they attempt to cover the broad concept of using an adjuvanted influenza vaccine in older adults.
The strongest method-of-use positions would normally require a specific formulation, dosing regimen, immunogenicity result, or patient subgroup. Broad age-based claims are less likely to block competing enhanced influenza vaccines.
How many patents cover FLUAD?
There is no reliable single number that represents the current FLUAD patent estate. The relevant portfolio includes historical MF59 families, product-specific families, manufacturing patents, international counterparts, and expired rights.
A meaningful patent-count analysis must separate:
- Pending applications from granted patents.
- Live claims from expired claims.
- U.S. rights from foreign rights.
- Product claims from process claims.
- Patent families from individual national filings.
- Claims that read on FLUAD from claims that cover only adjacent adjuvant technologies.
On that basis, FLUAD should be viewed as having a platform and know-how estate rather than a simple, high-value patent thicket. The regulatory license and manufacturing system are more important barriers than a publicly visible Orange Book-style patent list.
What is the FDA regulatory status of FLUAD Quadrivalent?
FLUAD Quadrivalent was FDA-approved in 2020 for adults aged 65 and older. Like other seasonal influenza vaccines, its strain composition is updated through annual regulatory supplements.
The quadrivalent format included two influenza B lineages. The World Health Organization determined that the B/Yamagata lineage was no longer circulating at meaningful levels, and U.S. manufacturers began transitioning to trivalent influenza vaccines for the 2024-25 season.
The change reduces the long-term commercial role of FLUAD Quadrivalent in the U.S. market. Seqirus has continued the FLUAD franchise through a trivalent product rather than relying on the quadrivalent product as the primary future formulation [4, 5].
What is the competitive landscape for FLUAD?
FLUAD competes in the enhanced influenza-vaccine segment for older adults.
| Vaccine |
Company |
Technology |
Primary competitive position |
| FLUAD |
Seqirus |
MF59-adjuvanted, inactivated |
Enhanced immune response for adults 65+ |
| Fluzone High-Dose |
Sanofi |
High-antigen-dose, inactivated |
High-dose strategy for adults 65+ |
| Flublok |
Sanofi |
Recombinant hemagglutinin |
Egg-free recombinant option |
| Standard-dose vaccines |
Multiple manufacturers |
Inactivated or live attenuated |
Broad seasonal supply and lower complexity |
The CDC’s Advisory Committee on Immunization Practices has recommended that adults aged 65 and older receive one of the preferred enhanced vaccines when available: an adjuvanted vaccine, a high-dose vaccine, or a recombinant vaccine. The recommendation does not establish a preference among those three categories [6].
FLUAD’s principal commercial differentiator is the MF59 adjuvant. Fluzone High-Dose uses increased antigen content, while Flublok uses recombinant production. These mechanisms create product differentiation but also make direct substitution dependent on physician, pharmacy, payer, and supply-chain decisions.
Which companies are challenging FLUAD?
No major U.S. commercial challenger has established a direct biosimilar or interchangeable product specifically targeting FLUAD.
Competitive pressure comes from:
- Sanofi’s Fluzone High-Dose.
- Sanofi’s Flublok recombinant vaccine.
- Other manufacturers supplying standard-dose influenza vaccines.
- Potential future adjuvanted vaccines using different platforms.
- International manufacturers with regional influenza-vaccine approvals.
The principal challenge is therefore market share competition, not a conventional Paragraph IV patent attack.
What generic entry risks exist for FLUAD?
Traditional generic entry risk is low because FLUAD is a biologic vaccine rather than a small-molecule drug. A generic manufacturer cannot rely on an ordinary Abbreviated New Drug Application to copy FLUAD.
A potential follow-on entrant would face:
- BLA or biosimilar regulatory requirements.
- Comparability of antigen content and immune response.
- Demonstration of adjuvant consistency.
- Seasonal strain updates.
- Clinical and analytical characterization.
- Manufacturing scale-up.
- FDA inspection and lot-release requirements.
- Distribution before the relevant influenza season.
The larger risk is substitution by another enhanced vaccine, not a direct copy. This risk exists during the remaining regulatory exclusivity period because competitors can develop products that do not rely on FLUAD’s protected reference-product data.
What patent litigation affects FLUAD?
There is no widely established U.S. patent litigation campaign comparable to major small-molecule pharmaceutical disputes involving FLUAD. The product’s competitive record is primarily regulatory and commercial.
Potential disputes could involve:
- MF59 composition claims.
- Adjuvant manufacturing processes.
- Antigen-adjuvant combinations.
- Vaccine filling and delivery systems.
- Contract manufacturing and supply obligations.
- Patent rights surrounding next-generation adjuvants.
The absence of a prominent Paragraph IV litigation record reduces near-term litigation risk. It does not eliminate the possibility of future process or platform disputes involving competing adjuvanted vaccines.
How strong is the FLUAD patent estate?
FLUAD’s patent estate is moderate as a practical commercial portfolio but weaker as a stand-alone exclusionary patent position.
| Factor |
Assessment |
| Core composition protection |
Weakened by the age of foundational MF59 technology |
| Regulatory exclusivity |
Meaningful through approximately 2027 for the original biologic reference product |
| Manufacturing know-how |
Strong practical barrier |
| Annual strain updates |
Creates recurring regulatory work but limited durable patent protection |
| Brand and physician familiarity |
Supports retention among older adults and vaccination providers |
| Biosimilar competition |
Limited near-term likelihood |
| Direct patent litigation risk |
Low based on the absence of a major public dispute |
| Competitive substitution risk |
Moderate to high from Fluzone High-Dose and Flublok |
The strongest protection is the combination of a licensed product, validated MF59 manufacturing, seasonal production capacity, established distribution, and reimbursement access.
What is the financial trajectory for FLUAD and Seqirus?
Seqirus does not publicly report standalone FLUAD or FLUAD Quadrivalent revenue. CSL reports Seqirus results at the business-segment level, which includes multiple influenza vaccines and related products.
CSL has reported strong growth in the Seqirus business, driven by influenza-vaccine demand, portfolio expansion, pricing, and supply execution. The reported figures should not be treated as FLUAD sales because Seqirus includes products such as Fluzone, Flucelvax, and other influenza vaccines in the same segment.
| Financial driver |
Effect on FLUAD |
| Aging U.S. population |
Expands the addressable 65+ population |
| Enhanced-vaccine recommendations |
Supports premium product demand |
| Medicare Part B coverage |
Reduces patient cost barriers |
| Annual seasonality |
Creates concentrated revenue in the fall vaccination period |
| Government contracts |
Can stabilize volume but pressure pricing |
| Quadrivalent-to-trivalent transition |
Requires product and inventory conversion |
| Manufacturing capacity |
Can constrain or support seasonal sales |
| Competitor supply shortages |
May increase opportunistic demand for FLUAD |
| Poor influenza season |
Can reduce vaccination urgency |
| Strain mismatch or low disease severity |
Can weaken seasonal revenue |
CSL’s FY2024 annual report identified Seqirus as a major growth business, but it did not provide a separate FLUAD revenue line [7]. The commercial model is therefore best evaluated through total Seqirus influenza revenue, U.S. enhanced-vaccine share, dose volumes, average selling price, and production capacity.
What is the revenue exposure to FLUAD?
FLUAD likely represents a meaningful but undisclosed portion of Seqirus’ U.S. influenza franchise. The product targets the highest-value influenza-vaccine segment, adults aged 65 and older, where enhanced vaccines generally command greater commercial importance than standard-dose products.
The exposure is not equivalent to total Seqirus influenza revenue. Investors should distinguish:
- FLUAD and FLUAD Quadrivalent.
- Flucelvax cell-based influenza vaccine.
- Fluzone products distributed through Seqirus arrangements or other channels.
- Government-purchased doses.
- Private-sector pharmacy and physician-office sales.
- International FLUAD and Fluad Tetra sales.
No public filing supports a precise product-level revenue estimate.
How does FLUAD compare with Fluzone High-Dose and Flublok?
| Attribute |
FLUAD |
Fluzone High-Dose |
Flublok |
| Company |
Seqirus |
Sanofi |
Sanofi |
| Technology |
MF59 adjuvant |
Increased antigen dose |
Recombinant antigen |
| Target group |
Adults 65+ |
Adults 65+ |
Adults 18+, including older adults |
| Manufacturing platform |
Egg-based influenza antigen with adjuvant |
Egg-based inactivated vaccine |
Recombinant production |
| Main differentiation |
Adjuvant-enhanced immune response |
Higher antigen quantity |
Egg-free recombinant design |
| Main risk |
Direct competition from other enhanced vaccines |
Capacity and price competition |
Manufacturing and clinical adoption |
| U.S. seasonal position |
Established enhanced vaccine |
Leading enhanced-vaccine competitor |
Alternative enhanced platform |
Clinical studies have generally shown that enhanced vaccines improve immune response or protection relative to standard-dose vaccines in older adults, but the evidence does not establish universal superiority of one enhanced product in every season or population [8].
What manufacturing and intellectual-property barriers affect FLUAD?
FLUAD’s manufacturing barriers are significant because influenza vaccine production must be completed on a seasonal schedule. The process requires:
- Timely strain selection.
- Antigen production.
- MF59 emulsion manufacture.
- Antigen-adjuvant blending.
- Sterile filling.
- Lot release.
- Distribution before peak vaccination demand.
Seqirus operates a global influenza manufacturing network, including facilities in the United States, the United Kingdom, and Australia. Manufacturing scale and continuity are strategic assets because a competitor cannot quickly replicate validated seasonal production capacity.
The main operational risks are supply interruptions, egg and antigen availability, fill-finish constraints, quality deviations, and delays in regulatory approval of seasonal composition updates.
What licensing deals support FLUAD?
FLUAD originated within the Chiron and Novartis influenza-vaccine businesses. CSL acquired Novartis’ influenza-vaccine business in 2015, creating Seqirus as a major global influenza-vaccine company [9].
The central transaction relevant to FLUAD is therefore the CSL acquisition of the Novartis influenza-vaccine business, rather than a recently disclosed product-specific licensing deal. Public filings do not identify a current external license fee or royalty stream specifically attributable to FLUAD.
MF59 technology and related know-how transferred through the historical Chiron-Novartis-Seqirus corporate chain. The commercial value of that platform is reflected in Seqirus’ broader influenza portfolio, not in a separately disclosed FLUAD royalty line.
What generic launch scenarios are realistic for FLUAD?
Scenario 1: No direct follow-on launch before 2027
This is the most likely near-term scenario. Competitors continue to take share through their own enhanced vaccines rather than introducing a FLUAD copy.
Scenario 2: Post-exclusivity biologic competitor
After the reference-product exclusivity period, a developer could pursue a follow-on product. Market entry would still require seasonal strain updates, manufacturing validation, and physician or payer adoption.
Scenario 3: Platform substitution
A competitor may bypass FLUAD’s MF59 technology by using a high-dose or recombinant platform. This is already the most relevant form of competition.
Scenario 4: Manufacturing-driven share shifts
A poor seasonal supply position at one manufacturer can transfer demand to competitors. This risk is more immediate than patent expiry because influenza vaccination demand is concentrated within a short annual window.
What geographic markets does FLUAD cover?
FLUAD and related products are marketed across multiple regions, subject to local regulatory approval and naming conventions.
| Market |
Product or regulatory position |
| United States |
FLUAD and FLUAD Quadrivalent historically; trivalent transition underway |
| European markets |
Fluad and Fluad Tetra naming varies by jurisdiction |
| United Kingdom |
Seasonal influenza products supplied through national procurement |
| Australia and other markets |
Local regulatory and procurement rules apply |
Geographic protection depends on separate national approvals, patent rights, procurement systems, and seasonal recommendations. A U.S. regulatory position does not automatically prevent competition in Europe, Australia, or other markets.
Key Takeaways
- FLUAD is Seqirus’ MF59-adjuvanted influenza vaccine for adults aged 65 and older.
- FLUAD Quadrivalent was approved in the United States in 2020, but the market is transitioning to trivalent influenza vaccines.
- The original FLUAD biologic exclusivity framework runs approximately through 2027.
- FLUAD does not have the standard Orange Book and Paragraph IV structure associated with small-molecule drugs.
- Foundational MF59 patent protection is old; manufacturing know-how, regulatory history, and seasonal capacity are more important current barriers.
- Direct biosimilar competition is limited, while Fluzone High-Dose and Flublok create substantial substitution risk.
- Seqirus does not disclose standalone FLUAD revenue.
- The product’s financial outlook is tied to growth in the older-adult population, enhanced-vaccine recommendations, Medicare coverage, annual influenza demand, and Seqirus manufacturing execution.
- FLUAD’s main risks are seasonal volatility, trivalent transition execution, competitor supply, pricing pressure, and future platform substitution.
FAQs About FLUAD Patent Protection and Market Outlook
Is FLUAD a biologic or a generic drug?
FLUAD is a biologic vaccine licensed under a BLA. It is not a conventional generic drug approved through an ANDA.
Is FLUAD covered by Medicare?
Influenza vaccination is generally covered under Medicare Part B without patient cost-sharing when administered by an eligible provider. Product-specific reimbursement depends on billing, site of care, and applicable Medicare rules.
Is FLUAD Quadrivalent still the main U.S. product?
No. U.S. influenza vaccines are transitioning to trivalent formulations following the removal of the B/Yamagata lineage from seasonal vaccine composition.
Does FLUAD have a biosimilar competitor?
No major direct U.S. biosimilar competitor has been established. The principal competition comes from other enhanced influenza vaccines, especially Fluzone High-Dose and Flublok.
What is the biggest commercial risk to FLUAD?
The largest commercial risk is substitution by competing enhanced vaccines combined with seasonal supply and demand volatility. Patent expiry is less immediate than competition from alternative vaccine technologies.
References
- U.S. Food and Drug Administration. (2015). FLUAD package insert and biologics license application 125363. FDA.
- U.S. Food and Drug Administration. (2020). FLUAD Quadrivalent approval and prescribing information. FDA.
- U.S. Congress. (2010). Patient Protection and Affordable Care Act, Section 7002: Biosimilar biological products. Public Health Service Act §351.
- U.S. Food and Drug Administration. (2024). 2024-2025 formula for influenza vaccines in the United States. FDA.
- World Health Organization. (2023). Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season. WHO.
- Centers for Disease Control and Prevention. (2024). Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2024-25 influenza season. CDC.
- CSL Limited. (2024). Annual report 2024. CSL Limited.
- Centers for Disease Control and Prevention. (2024). Influenza vaccination: People 65 years and older. CDC.
- CSL Limited. (2015). CSL completes acquisition of Novartis influenza vaccines business. CSL Limited.
